Press Release
Delphi Diagnostics Co-Founder and Lead Inventor W. Fraser Symmans Honored with a Brinker Award by the Susan G. Komen® Foundation
A PDF of the release can be found here
Houston, TX, December, 2025 – Delphi Diagnostics recognizes our co-founder and lead inventor, W. Fraser Symmans, who was honored by the Susan G. Komen Foundation with a Brinker Award for Scientific Distinction in Clinical Research. This award was presented during the San Antonio Breast Cancer Symposium in December 2025. Established in 1992, Susan G. Komen’s Brinker Awards for Scientific Distinction recognize pioneering work in breast cancer research and treatment.
Dr. Fraser Symmans is a Professor in the Departments of Pathology and Translational Molecular Pathology at the University of Texas MD Anderson Cancer Center in Houston TX, where he practices Breast Surgical Pathology and Cytopathology and directs the Breast Cancer Pharmacogenomics Laboratory. Dr. Symmans is the lead inventor of the technology behind the Endocrine Activity Index® (EAI®) test, known in scientific publications as SET.
To read the full press release issued by the Susan G. Komen® Foundation, please click here.
To learn more about the technology behind the EAI test, visit: https://delphi-diagnostics.com/our-technology/
*EAI is known as SET in scientific literature, and EAIRR is known as SET2,3
Dr. Symmans has a personal financial relationship with Delphi that has been identified as a conflict of interest and is managed by MD Anderson’s Conflict of Interest Committee.
About EAI
Delphi Diagnostics’ Endocrine Activity Index® (EAI™) test can provide actionable information for prognosis and prediction of dose-intense taxane-based chemotherapy benefit in stage II-III, HR+ HER2- breast cancer. The EAI measures endocrine activity in a breast tumor and for prognostic use, the Index Score is adjusted for baseline prognosis using molecular subtype genes (RNA4) and clinical factors such as tumor size and regional lymph node involvement. The EAI test has been shown in various studies to be a consistent prognostic indicator for long-term outcomes in stage II-III breast cancer patients, to be independent of other prognostic tests, as well as to be predictive for response to dose-dense chemotherapy.
About DELPhi Diagnostics
Delphi Diagnostics Inc. is a Texas-based company focused on advancing clinically valid tests for the prognosis and prediction of breast cancer treatment. Delphi Diagnostics, Inc. holds an exclusive license from The University of Texas MD Anderson Cancer Center in Houston, TX to commercialize the Endocrine Activity Index, a technology that was developed by the laboratory of Dr. W. Fraser Symmans**. The Endocrine Activity Index (EAI) test measures endocrine activity in stage II-III, HR+HER2- breast cancer. Delphi’s vision is to make the EAI test available to breast cancer patients and open new pathways for personalized breast cancer treatment. To learn more, visit www.delphi-diagnostics.com.
Contact Delphi Diagnostics
Emily Granger
Delphi Diagnostics Inc.
egranger@delphi-diagnostics.com
508.341.9331